# Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions

> **NCT05290948** · PHASE2 · UNKNOWN · sponsor: **Shahid Beheshti University of Medical Sciences** · enrollment: 57 (estimated)

## Conditions studied

- Macular Edema

## Interventions

- **DRUG:** intravitreal injection of bevacizumab with acetazolamide tablets
- **DRUG:** intravitreal injection of bevacizumab

## Key facts

- **NCT ID:** NCT05290948
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-12
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2022-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05290948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05290948, "Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05290948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*